New Anti-Angiogenesis Target: a Dual-Ligand Receptor
|Organization:||Boston University, MA, US|
|I.P. Brief:||The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-l/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.|
|Keywords:||Angiogenesis, Cancer, VEGF|
|Primary Industry:||Pharma & Biotech|
|Specific Market:||Cancer Therapy|
Full IP Descriptions available on-site.